Citation

Al-Amer O. Ann. Trop. Med. Public Health 2015; 8(5): 159-163.

Copyright

(Copyright © 2015, Medknow Publications)

DOI

10.4103/1755-6783.159851

PMID

unavailable

Abstract

Malaria is one of the most common infectious diseases, resulting in the deaths of millions of children around the world. The disease causes approximately half a million to 2.5 million people to die annually. People can only get malaria by being bitten by an infective female Anopheles mosquito that transmits malaria from infected individuals. The increase in international travel and the spread of malaria around the world has resulted in an increased risk of malaria infection. Prophylactic drugs are used to prevent the spread of malaria and to protect individuals in endemic areas. The most efficacious drug for treatment and prophylaxis against malaria is mefloquine (MQ), an antimalarial drug used especially as a prophylaxis against Plasmodium falciparum and as a treatment for malaria. MQ is also used to prevent the treatment of chloroquine-resistant P. falciparum malaria. This review focuses on the advantages of MQ and its adverse events.

Language: en

Keywords

human; Review; insomnia; depression; psychosis; suicide attempt; fatigue; vomiting; mental disease; headache; vertigo; sleep disorder; neurotoxicity; malaria; nonhuman; drug safety; seizure; drug efficacy; risk benefit analysis; diarrhea; nausea; delirium; nightmare; side effect; pruritus; heart palpitation; disease transmission; infection risk; infection prevention; dizziness; travel; acute psychosis; chloroquine; blurred vision; mefloquine; Malaria; Plasmodium falciparum; malaria falciparum; Anopheles; endemic disease; mefloquine (MQ); neuropsychiatric